Want to see KR:001360 full AI Analyst Report?

SAMSUNG PHARMACEUTICAL.CO.,Ltd. (001360) Price & Analysis

― Followers

001360 Stock Chart & Stats

₩1203.00

-₩27.00(-2.20%)

Oct 30, 2026

―

Day’s Range― - ―

52-Week Range₩1,140.00 - ₩2,320.00

Previous CloseN/A

VolumeN/A

Average Volume (3M)343.02K

Market Cap

₩113.23B

Enterprise Value₩134.50B

Total Cash (Recent Filing)₩9.56B

Total Debt (Recent Filing)₩18.60B

Price to Earnings (P/E)―

Beta0.26

Next Earnings

Nov 18, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1451.04

Shares Outstanding94,162,080

10 Day Avg. Volume201,068

30 Day Avg. Volume343,021

Financial Highlights & Ratios

PEG Ratio-0.07

Price to Book (P/B)1.19

Price to Sales (P/S)3.13

P/FCF Ratio-14.26

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Moderate LeverageModerate leverage provides a comparatively sound solvency base and limits immediate dependence on debt financing. This gives Samsung Pharmaceutical greater flexibility to manage its operations and pursue improvements while reducing the balance-sheet strain that can accompany heavier borrowing.

Established Pharmaceutical PortfolioParticipation across OTC, prescription, and related healthcare products gives the company an established pharmaceutical platform rather than reliance on a single product category. Distribution through medical and retail channels can support broader customer access and recurring commercial opportunities.

Gross Margin BaseA gross margin near 39% indicates that the products retain meaningful economic value before operating costs are deducted. If management can improve cost discipline and operating efficiency, this existing gross-profit base could provide a foundation for restoring positive operating earnings over time.

Bears Say

Persistent Cash BurnPersistent negative operating and free cash flow shows that the core business is not currently funding itself. Continued cash burn can increase reliance on external funding or existing balance-sheet resources, reducing financial flexibility and raising risk if operating losses continue.

Weak ProfitabilityThe combination of declining revenue, a large net loss, and deeply negative operating margins points to weak earnings power rather than a temporary margin squeeze alone. Without a sustained improvement in operating profitability, the company may struggle to convert its product base into durable shareholder returns.

Earnings VolatilityThe sharp reversal from annual profit to sizable TTM losses demonstrates limited earnings consistency. Volatile results make planning and capital allocation more difficult, while deeply negative returns on equity indicate that the existing capital base is currently producing poor economic returns.

001360 FAQ

What was SAMSUNG PHARMACEUTICAL.CO.,Ltd.’s price range in the past 12 months?

SAMSUNG PHARMACEUTICAL.CO.,Ltd. lowest stock price was ₩1140.00 and its highest was ₩2320.00 in the past 12 months.

What is SAMSUNG PHARMACEUTICAL.CO.,Ltd.’s market cap?

SAMSUNG PHARMACEUTICAL.CO.,Ltd.’s market cap is ₩113.23B.

When is SAMSUNG PHARMACEUTICAL.CO.,Ltd.’s upcoming earnings report date?

SAMSUNG PHARMACEUTICAL.CO.,Ltd.’s upcoming earnings report date is Nov 18, 2026 which is in 18 days.

How were SAMSUNG PHARMACEUTICAL.CO.,Ltd.’s earnings last quarter?

SAMSUNG PHARMACEUTICAL.CO.,Ltd. released its earnings results on Aug 14, 2026. The company reported -₩601.844 earnings per share for the quarter.

Is SAMSUNG PHARMACEUTICAL.CO.,Ltd. overvalued?

According to Wall Street analysts SAMSUNG PHARMACEUTICAL.CO.,Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does SAMSUNG PHARMACEUTICAL.CO.,Ltd. pay dividends?

SAMSUNG PHARMACEUTICAL.CO.,Ltd. does not currently pay dividends.

What is SAMSUNG PHARMACEUTICAL.CO.,Ltd.’s EPS estimate?

SAMSUNG PHARMACEUTICAL.CO.,Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does SAMSUNG PHARMACEUTICAL.CO.,Ltd. have?

SAMSUNG PHARMACEUTICAL.CO.,Ltd. has 94,162,080 shares outstanding.

What happened to SAMSUNG PHARMACEUTICAL.CO.,Ltd.’s price movement after its last earnings report?

SAMSUNG PHARMACEUTICAL.CO.,Ltd. reported an EPS of -₩601.844 in its last earnings report. Following the earnings report the stock price went up 0.849%.

Which hedge fund is a major shareholder of SAMSUNG PHARMACEUTICAL.CO.,Ltd.?

Currently, no hedge funds are holding shares in KR:001360

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

SAMSUNG PHARMACEUTICAL.CO.,Ltd.

SAMSUNG PHARM. Co., LTD. is a South Korean pharmaceutical company engaged in the manufacturing and distribution of a wide array of medical products. Its extensive portfolio includes a variety of prescription medications, encompassing treatments for conditions such as cancer (immunotherapy), pain, fever, and inflammation, obesity, high blood pressure, and arterial hardening, along with remedies for digestive disorders, phlegm, enzyme deficiencies, and osteoporosis. The company also supplies transfusion agents, skeletal muscle relaxants, antispasmodics, mixed vitamins, and antibiotics. Beyond these, SAMSUNG PHARM. provides general health and wellness products, including digestive aids, liver and circulatory system medications, cold remedies, nutritional supplements, health tonics, vitamins, energy drinks, and functional foods. Founded in 1929, the firm maintains its headquarters in Hwaseong-si, South Korea.